FDA Grants Dasatinib Priority Review for Resistant CML

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 4
Volume 15
Issue 4

The FDA has granted priority review to dasatinib (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults.

PRINCETON, New Jersey—The FDA has granted priority review to dasatinib (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults. Dasatinib, an oral, small-molecule tyrosine kinase inhibitor, exhibits greater potency than imatinib and inhibits the majority of kinase mutations resistant to imatinib. The new drug application also seeks approval of dasatinib for treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Articles in this issue
Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLC
ONS Annual Congress Heralds Start of Oncology Nursing Month
All-Star Panel Spells Out Onc Promises, Problems
Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosis
ODAC Says No to Gemzar for Ovarian Ca
Experts See Oncology Reimbursements Headed Down, Hard Negotiations With Payers Lie Ahead
Femara Effective Even After Years of No Therapy
XMRV Retrovirus Found in Some Prostate Ca's
Taxotere Wins FDA Approval for Advanced Gastric Cancer
Community Oncology Practices Struggle to Cope With the Extra Requirements of Medicare Part D
Director of NCI Nominated as New FDA Commissioner
TAM-01 Finds Longer Tamoxifen Duration Is Not Better
Erbitux Wins Approval for Squamous Cell H&N Cancer
Young Doctors Are Hungry for Psychological Oncology Training
Posaconazole Reduces Serious IFIs in High-Risk Patients
Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024
Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management

February 5th 2024
Podcast

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL

STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL

April 15th 2024
Article

Additional data and results from the phase 3 STARGLO trial of glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma will be presented at an upcoming medical meeting.

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

November 3rd 2022
Podcast

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

COVID-19 and Chemotherapy Association Holds in Pediatric Leukemia/Lymphoma

April 12th 2024
Article

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML

April 12th 2024
Article

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.